BER is a double-edged sword in cancer therapy. On one hand, cancer cells rely on BER to repair the DNA damage caused by chemotherapy and radiation, making them more resistant to treatment. On the other hand, targeting BER enzymes can sensitize cancer cells to these therapies. Inhibitors of BER enzymes, such as PARP inhibitors, have been developed to enhance the efficacy of DNA-damaging agents by preventing the repair of DNA damage in cancer cells.
